-
3 weeks ago | 
nature.com | Marc S. Raab |Yael Cohen |Fredrik Schjesvold |Andrew Spencer |Martin Wermke |Anita Souza | +6 more
Correction to: Leukemia https://doi.org/10.1038/s41375-023-01883-3, published online 06 April 2023In this article the wrong figure appeared as Fig. 3a; the figure should have appeared as shown below. The original article has been corrected. About this articleRaab, M.S., Cohen, Y.C., Schjesvold, F. et al. Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia (2025).
-
Jan 20, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 20, 2025By Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.
-
Jan 20, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 20, 2025By Panelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.
-
Jan 20, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 20, 2025By Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.
-
Jan 10, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 10, 2025 By Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient...
-
Jan 10, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 10, 2025By Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.
-
Dec 20, 2024 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
December 20, 2024By Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.
-
Oct 11, 2024 | 
digitalcommons.library.tmc.edu | Ajai Chari |Jonathan Kaufman |Jacob P. Laubach |Douglas Sborov
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]).
-
Sep 18, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MMThe relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.
-
Sep 11, 2024 | 
onclive.com | Robert Orlowski |Jonathan Kaufman
OpinionVideoSeptember 11, 2024Author(s):The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies. Video content above is prompted by the following:What is your treatment sequencing approach for those who already received T-cell engaging therapies? What are some treatment options for those who have already received T-cell directed therapies in the R/R MM setting?
